The through-line today is unmistakable: the pharmaceutical industry is betting bigger than ever on artificial intelligence, even as regulators quietly reshape how much of their own decision-making the public gets to see.
AI Moves to the Center of Drug Discovery
The headline deal comes out of Japan, where Takeda Pharmaceutical (TSE:4502) has partnered with Insilico Medicine to put the biotech's Pharma.AI platform to work hunting for new drugs, according to Pharmaceutical Business Review and simplywall.st. It's a marquee validation of AI-driven discovery from one of the world's larger drugmakers — and Insilico isn't slowing down. The company is also taking a leading role alongside pharma giant Eli Lilly at Harvard's 13th ARDD Meeting, a signal of how central AI-focused biotechs have become to the field's marquee gatherings.
The momentum is industry-wide. A cluster of reports gathered by citybiz describes pharma leaning harder on AI to sift data, discover drugs, and guide research decisions — from a $1.4 billion heart-drug push to an analytics overhaul in India. The money follows the enthusiasm: a forecast circulated by GlobeNewswire and picked up by outlets including Yahoo Finance projects the generative-AI-in-pharma market to reach $9.36 billion by 2030, a steep climb from where it stands today.
Not every AI bet is basking in praise. Recursion Pharmaceuticals (RXRX) is back in the spotlight — and under fresh scrutiny — over its high-profile wager on applying AI to biotechnology, according to Quiver Quantitative. And on the clinical-tools front, a new AI-powered approach to FFR (fractional flow reserve, a measure of blood flow through the heart's arteries) is showing early promise in heart imaging, per Cardiovascular coverage.
The FDA Opens Up — and Says No, Again
Regulators made news on transparency. The FDA is once again publishing the letters it sends drug companies when it declines to approve a product, posting 14 new rejection letters online on Friday, Endpoints News reports — a reversal that pulls back the curtain on decisions that are usually kept private.
One of those decisions landed hard for the third time: the FDA again refused to approve the liver cancer treatment developed by China's Jiangsu Hengrui Pharmaceuticals and its U.S. partner Elevar Therapeutics, marking a third rejection for the drug. Meanwhile, Cambridge-based Apnimed is pressing ahead with a Nasdaq IPO after years of weighing the move — even as the FDA weighs its sleep apnea drug, per Endpoints.
Money, Programs, and People
The U.S. government's health-research agency ARPA-H is committing $160 million to develop 'bespoke,' made-to-order gene-editing therapies — personalized medicines tailored to individual patients, according to BioPharma Dive. It's one of the more ambitious public bets on custom drug development.
Elsewhere, a promising program got a second life: Cellular Intelligence has picked up a Parkinson's stem cell therapy that Novo shelved, giving an abandoned program a new home, Endpoints reports. And Pfizer reshuffled its leadership in the fiercely competitive obesity race, promoting Danna Breen to head of obesity discovery — a move first surfaced on LinkedIn.
Taken together, the day paints a familiar but sharpening picture: capital and talent are pouring into AI-guided discovery and next-generation therapies, while the FDA both throws open its files and keeps saying no. The bets are getting bigger; so are the stakes.